P-127 - CLINICAL PHARMACOLOGY LEARNINGS FROM FDA-APPROVED HEMATOLOGY-ONCOLOGY THERAPEUTICS (ACROSS MODALITIES & ACROSS DISEASE INDICATIONS): LAST 5 YEARS.

S. Nozohouri¹, J. Kast², D. Zhou³, M. Yago³, H. Wong⁴, X. Zhang³, V. Upreti³; ¹Texas Tech University Health Sciences Center, Amarillo, TX, USA, ²Amgen Inc., San Francisco, CA, USA, ³Amgen Inc., South San Francisco, CA, USA, ⁴Amgen Inc., San Fransisco, CA, USA.